Axogen agreed to acquire BioCircuit Technologies for a base cash price of $200.0 million and plans to fund the transaction with proceeds from a 4,910,000-share offering. Investors must weigh the deal’s closing conditions, required financing, potential integration challenges and the company’s 30-day option for 736,500 additional shares.
Key Highlights
- Axogen agreed to sell 4,910,000 common shares at a public offering price of $42.50 per share.
- Underwriters received a 30-day option to buy up to 736,500 additional common shares.
- BioCircuit’s products include NerveTape and ConformaWrap for peripheral nerve repair.
Axogen, Inc. (NASDAQ: AXGN) agreed to acquire BioCircuit Technologies for a base cash purchase price of $200.0 million. The transaction would make BioCircuit a wholly owned subsidiary, while Axogen intends to use substantially all net proceeds from a common-stock offering to fund the cash consideration and related costs.
$42.50 Offering Supports Acquisition Axogen
agreed to sell 4,910,000 shares of common stock at a public offering price of $42.50 per share. Underwriters will pay $39.95 per share, and they received a 30-day option to purchase up to 736,500 additional shares. The stock has a Par Value of $0.01 per share, and the offering is expected to close on September 11, 2026. BioCircuit develops and commercializes NerveTape and ConformaWrap for repairing peripheral nerve discontinuities. Before the transaction closes, BioCircuit will distribute an unrelated electronics Business to its stockholders.
Closing Conditions Extend Through December 31 The
transaction is expected to close in the fourth quarter of 2026, subject to customary conditions. Those include consent under an inbound intellectual property license, conversion of BioCircuit’s outstanding convertible promissory notes into common stock and completion of the electronics business spin-out. Axogen agreed to obtain sufficient transaction funding within 90 days of executing the Merger agreement, although the acquisition is not subject to a financing condition. Either party may terminate if the merger has not closed by December 31, 2026, and the agreement provides no termination fee. The company identified integration difficulties, costs and management attention as risks that could affect anticipated benefits if the transaction closes.




Please wait processing your request...